Replies to post #43183 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

I am not selling, wasn’t a short play for me regardless of EUA. Aviptadil is a revolutionary treatment for ARDS, acute respiratory distress syndrome. Had COVID never come along, they would still be working toward the same end. Maybe they would have stayed away from Neuro and moved this faster in Europe, then US. I still see success on the horizon, just more distant. ARDS is a difficult to treat condition, once someone ends up on a vent, chances of survival decrease precipitously. Aviptadil can help prevent the vent and restore lung capacity. Stay the course, we made it this far.

~ Amanda, Y@h00 RLFTF finance conversations

[PennyWorld]

Changes...I agree. Fool me once, shame on you. Fool me twice, shame on me.

I wonder if it is too late (or legally not possible per the CA) for RAM to bring in a bigger, more experienced pharmaceutical company to help close this EUA deal? RLFTF authored the CA, and NRXP is simply the contractor.

RLFTF is a major stakeholder in the CA, so it would seem to me that RAM has some leverage and say so in the matter of bringing in another partner to close the deal.

[changes_iv]

I did not see the FDA asking for more data/testing on toxic vaccines.

https://rumble.com/vk23ha-patient-asserts-sudden-neurological-disorder-caused-by-covid-vaccine.html

RLF-100/AVIPTADIL may help the afflicted with a neurological disorder after a toxic jab(s)

In the central and peripheral nervous system, vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide, is released to support neuronal survival in both physiological and pathological condition. VIP can inhibit the neurodegeneration induced by the loss of neurons.

https://pubmed.ncbi.nlm.nih.gov/27786097/

There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimers disease, Parkinsons disease, and Autism Spectrum Disorders.

https://www.eurekaselect.com/node/94030/article/-therapeutic-potential-of-vasoactive-intestinal-peptide-and-its-receptors-in-neurological-disorders